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Small-molecule activation of lysosomal TRP channels 
ameliorates Duchenne muscular dystrophy  
in mouse models
Lu Yu1, Xiaoli Zhang1, Yexin Yang1, Dan Li1,2, Kaiyuan Tang1, Zifan Zhao1, Wanwan He1,2, 
Ce Wang1, Nirakar Sahoo1,3, Kimber Converso-Baran4, Carol S. Davis4, Susan V. Brooks4, 
Anne Bigot5, Raul Calvo6, Natalia J. Martinez6, Noel Southall6, Xin Hu6, Juan Marugan6, 
Marc Ferrer6, Haoxing Xu1*
Duchenne muscular dystrophy (DMD) is a devastating disease caused by mutations in dystrophin that com-
promise sarcolemma integrity. Currently, there is no treatment for DMD. Mutations in transient receptor potential 
mucolipin 1 (ML1), a lysosomal Ca2+ channel required for lysosomal exocytosis, produce a DMD-like phenotype. 
Here, we show that transgenic overexpression or pharmacological activation of ML1 in vivo facilitates sarcolemma 
repair and alleviates the dystrophic phenotypes in both skeletal and cardiac muscles of mdx mice (a mouse model 
of DMD). Hallmark dystrophic features of DMD, including myofiber necrosis, central nucleation, fibrosis, elevated 
serum creatine kinase levels, reduced muscle force, impaired motor ability, and dilated cardiomyopathies, were 
all ameliorated by increasing ML1 activity. ML1-dependent activation of transcription factor EB (TFEB) corrects 
lysosomal insufficiency to diminish muscle damage. Hence, targeting lysosomal Ca2+ channels may represent a 
promising approach to treat DMD and related muscle diseases.
INTRODUCTION
Duchenne muscular dystrophy (DMD), an X-linked inherited muscle 
disease (1), is caused by loss-of-function mutations affecting dys-
trophin, a large cytoplasmic protein that connects the cytoskeleton 
with extracellular matrix proteins via the muscle membrane (sarco-
lemma) (2, 3). The fragile sarcolemma that makes human DMD 
muscles prone to contraction-induced muscle damage is mimicked 
in the striated muscles of the mdx mouse, a murine model of DMD 
(4–6). Although gene therapy approaches, including CRISPR-Cas9 
technology (7), have provided hope for potential treatment to some 
specific variants of DMD, the existence of thousands of DMD-causing 
dystrophin mutations remains a major challenge (1). To develop a 
therapeutic approach that would be more broadly applicable to all 
forms of DMD, it is necessary to understand the common pathological 
mechanisms underlying the condition (4).
Muscle cells are especially sensitive to membrane damage, and 
recent studies have identified impairment of membrane repair ca-
pability as an important cause of muscular dystrophies (8–10). For 
instance, we recently found that mice lacking transient receptor 
potential mucolipin 1 (TRPML1/MCOLN1; ML1), a lysosomal Ca2+ 
release channel required for lysosomal exocytosis (11, 12), display 
early-onset, progressive dystrophies similar to DMD (13). When ML1 
is pharmacologically inhibited or genetically inactivated, membrane 
resealing is impaired in skeletal muscles (13). Hence, lysosomes may 
provide a major source of membranes for repairing damaged sarco-
lemma, and ML1 is essential for Ca2+-dependent delivery of lyso-
somal membranes (i.e., lysosomal exocytosis) to damaged sites (13). 
Studies of other muscle diseases have also connected lysosomal dys-
function with muscle pathogenesis (14).
In the current proof-of-concept study, we examined whether up- 
regulation of ML1, by genetic or pharmacological methods, is sufficient 
to increase lysosomal functions and sarcolemma repair. If so, ML1 
may be a putative target for amelioration of muscle damage in vivo.
RESULTS
Transgenic overexpression of ML1 ameliorates muscular 
dystrophies in mdx mice
To achieve muscle-specific overexpression of ML1 in vivo, we crossed 
a mouse line carrying a GCaMP3-ML1 transgene (ML1 ROSA-lSl) 
(15) with a Cre line driven by the muscle-specific creatine kinase (CK) 
promoter (MCK-Cre) (16). The resultant ML1 ROSA-lSl;MCK-Cre 
(abbreviated as ML1MCK) progeny were then crossed with mdx 
mice with a loss-of-function dystrophin mutation (17) to generate 
mdx;ML1MCK mice (Fig. 1A and fig. S1A). Western blotting and im-
munofluorescence analyses with anti-ML1 antibody revealed ML1 
overexpression in both skeletal and cardiac muscle tissues of the 
mdx;ML1MCK mice; isolated primary myotubes were ML1 immuno-
positive, whereas nonmuscle tissues showed barely detectable im-
munoreactivity (Fig. 1, B to D, and fig. S1, B and C).
Whole-lysosomal ML1 currents, activated by TRPML-specific 
synthetic agonists (ML-SAs) (12, 15, 18), were 4 to 10 times larger in the 
ML1MCK myotubes than in wild-type (WT) controls (Fig. 1, E and F). 
ML-SAs induced robust glycyl-l-phenylalanine 2-naphthylamide–
sensitive lysosomal Ca2+ release (15) in ML1MCK myotubes, suggesting 
that genetically overexpressed ML1 channels were functionally localized 
on the late endosomal and lysosomal membranes of muscle cells 
(Fig. 1, G to I, and fig. S1, D and E). Introducing ML1MCK into the 
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Fig. 1. Muscle-specific transgenic overexpression of ML1. (A) PCR genotyping of the mdx mutation, GCaMP3-ML1 transgene, and MCK-Cre. (B) Western blotting with 
anti-ML1 antibody in brain and various skeletal muscle tissues, including GAS, TA, and DIA from WT, ML1 ROSA-lSl;MCK Cre (ML1MCK), mdx, and mdx;ML1MCK mice (see 
fig. S1B for the source files). GAPDH served as the loading control. Note that MCK-Cre is selectively expressed in differentiated myotubes (16), and its expression in the muscle 
tissue might be affected by the degree of dystrophies. (C) Immunofluorescence analysis of TA, GAS, and DIA cryosections from various transgenic mice. Scale bar, 10 m. 
(D) Immunofluorescence analysis of primary myotubes isolated from ML1MCK mice. Scale bar, 10 m. (E) Whole-endolysosome ML1 currents (IML1) were activated by 
ML-SA1 (20 M), a synthetic agonist of ML1, in primary myotubes harvested from WT, ML1MCK, mdx, and mdx;ML1MCK mice. Currents were stimulated with a ramp voltage 
protocol from −120 to +60 mV. Holding potential = 0 mV. (F) IML1 current densities of myotubes from (E). Each open circle represents one cell/patch. (G) Structure of 
ML-SA5. (H and I) ML-SA5–induced lysosomal Ca2+ release, measured with GCaMP3 imaging, in primary myotubes isolated from ML1MCK mice. GPN (glycyl-l-phenylalanine 
2-naphthylamide), a dipeptide causing osmotic lysis of lysosomes, was used as a negative (depleting lysosomal Ca2+ stores) control. (J) Representative images showing 
H&E staining of GAS isolated from 2-month-old ML1−/− and ML1−/−;ML1MCK mice. Arrows label necrotic areas, and asterisks show centrally nucleated myofibers. Scale bar, 100 m. 
(K and L) Quantification of necrosis (K) and central nucleation (L) in GAS sections from 2-month-old ML1−/− and ML1−/−;ML1MCK mice. All data are means ± SEM; *P < 0.05, 
**P < 0.01, ***P < 0.001.
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ML1 knockout (KO) mice resulted in a complete rescue of the dys-
trophic phenotype, as manifested by the decreases in myofiber 
necrosis and central nucleation (Fig. 1, J  to L) (13). Hence, the 
ML1MCK mice were considered suitable for investigating the in vivo 
effects of ML1 overexpression on striated muscles.
Mdx mice, either homozygous females or hemizygous males, 
exhibit early-onset muscular dystrophies, as evidenced by myofiber 
necrosis (myonecrosis) and degeneration/regeneration cycles, which 
were readily observed by postnatal day 14 (P14) (19). In 1-month-old 
mdx;ML1MCK mice, hematoxylin and eosin (H&E) staining revealed 
that myonecrosis, quantified by the percentage of the necrotic area 
(i.e., the presence of necrotic myofibers, immune cells, and fibro-
blasts) in whole cross sections, was markedly reduced in tibialis 
anterior (TA) muscles compared with age-matched mdx mice, 
especially after downhill treadmill exercise (Fig. 2, A and B). The 
number of centrally nucleated fibers, caused by repeated myocyte 
degeneration and regeneration, was also significantly reduced in the 
mdx;ML1MCK muscles (Fig. 2, A and C). Similar anti-dystrophic effects 
were seen in other skeletal muscles, including the gastrocnemius (GAS) 
and diaphragm (DIA) (fig. S2, A to G). Serum CK levels, a diagnostic 
biomarker of DMD (13), were also reduced by ML1 overexpression 
(Fig. 2D). Consistent with the histological and biochemical results, 
physiological assays showed improved specific muscle force in mdx 
mice following ML1MCK overexpression (Fig. 2E).
In most skeletal muscles of mdx mice, the dystrophic phenotype did 
not appear to be progressive, perhaps due to compensatory expres-
sion of utrophin, a functional homolog of dystrophin (20). Relative to 
mdx mice, utrophin−/−;mdx mice have a much more severe and pro-
gressive muscular dystrophy that resembled human DMD (20). Both 
dystrophy and body weight loss characteristic of the utrophin−/−;mdx 
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Fig. 2. Transgenic overexpression of ML1 reduces muscle pathologies in young mdx mice. (A) H&E staining of TA sections from WT, ML1MCK, mdx, and mdx;ML1MCK 
mice at the age of 1 month, before (rest) and after treadmill exercise. Both male and female mice were randomly assigned into different groups. Arrows label necrotic 
areas and asterisks show centrally nucleated myofibers. Scale bar, 500 m or 50 m (zoom-in images). (B) Percentage of necrotic area in TA muscles from various trans-
genic mice. Each datum (n indicates the number of the muscle) represents the averaged result from at least five representative images randomly selected from at least 
three sections. Statistical analyses were performed by experimenters who were blind to animal genotypes. (C) Percentage of centrally nucleated fibers in TA muscles from 
different transgenic mice. (D) Serum CK levels in 1-month-old WT, ML1MCK, mdx, and mdx;ML1MCK mice before and after treadmill exercise. (E) Specific force test of GAS 
from multiple 1-month-old mice. (F) Body weight measurements of WT, utrophin−/−;mdx (utrn−/−;mdx), and utrn−/−;mdx;ML1MCK male mice at the age of 1 month. (G) Effect 
of ML1 overexpression on histology of TA muscles isolated from 2-month-old utrn−/−;mdx mice. Scale bar, 50 m. (H) Quantification on central nucleation of muscle histology 
from (G). All data are means ± SEM; *P < 0.05, **P < 0.01, and ***P < 0.001.
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phenotypes (20) were improved by ML1MCK overexpression (Fig. 2, 
F to H). Dystrophy of the DIA in mdx mice was also progressive, as 
seen in human DMD, and respiratory failure is a major cause of 
death in DMD (6). Consistent with previous studies (6), we observed 
massive necrosis and subsequent fibrous and adipose tissue replace-
ment (i.e., fibrosis) in mdx DIA muscles (Fig. 3, A and B). At all ages 
examined (1, 4, and 10 months), fibrosis was reduced significantly 
by ML1MCK overexpression (Fig. 3, A and B). The content of collagen, 
a major component of fibrous scar tissue (13), was also decreased by 
ML1MCK overexpression (Fig. 3, C and D).
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Cardiac failure is another major cause of death in DMD, but cardio-
myopathies are observed only in aged (e.g., >10-month-old) mdx 
mice (21, 22). We performed echocardiograms in 13- to 15-month-old 
WT, mdx, and mdx;ML1MCK male mice (fig. S2H). Compared with 
WT mice, mdx mice had thickened interventricular septum (IVS) 
and increased left ventricle mass (Fig. 3, E to G), both of which are 
characteristic of dilated cardiomyopathies (21). Both echocardio-
graphic abnormalities were ameliorated by ML1 overexpression 
(Fig. 3, E to G). We also performed pulse-wave Doppler echocardio-
graphy to analyze the contractile function of the left ventricle (fig. 
S2I). Consistent with previous studies (23), mdx hearts had reduced 
E wave velocity and E/A ratio (Fig. 3, H and I), suggestive of ventric-
ular dysfunction. Both parameters were corrected by ML1MCK over-
expression (Fig. 3, H and I). Histological analyses showed that cardiac 
fibrosis in aged (15-month-old) mdx mice was also reduced by ML1MCK 
expression (Fig. 3J and fig. S2J). Together, these results suggest that 
transgenic overexpression of ML1 is sufficient to attenuate dystrophies 
of both skeletal and cardiac muscles in DMD-like mouse models.
Pharmacological activation of ML1 in vivo ameliorates 
muscular dystrophy in mdx mice
Next, we tested whether small-molecule ML1 agonists have a muscle 
protective effect in mdx mice. ML-SA5, a potent ML-SA compound 
with an in vitro EC50 (median effective concentration) value in the 
nanomolar range for endogenous ML1 (Figs. 1G and 4A), exhibited 
pharmacokinetic properties suitable for in vivo studies (fig. S3A). 
Mdx mice received daily intraperitoneal injection of ML-SA5, start-
ing at P14 and continuing for at least 2 weeks. Like the vehicle [10% 
dimethyl sulfoxide (DMSO) + 40% polyethylene glycol (PEG) + 
50% phosphate-buffered saline (PBS)]–treated group, no patholog-
ical signs were evident following ML-SA5 injection, manifested by 
normal body weight, complete blood count, liver biochemistry and 
histology, and kidney histology (fig. S3, B to J), suggesting the minimal 
toxicity effects. However, at the intraperitoneal dose of 2 to 5 mg/kg, 
daily ML-SA5 injection for 2 weeks decreased TA muscle necrosis 
by more than 70%, both at rest and after treadmill exercise (Fig. 4, 
B and C). Centrally nucleated fibers were also decreased in the ML-
SA5–injected mdx mice (Fig. 4, B and D). Similar rescue effects were 
also seen in the GAS and DIA muscles (fig. S4, A to F). Consistently, 
serum CK level was also reduced in mdx mice that received ML1 
agonist injection (Fig. 4E). In contrast, intraperitoneal injection of 
ML-SI6, a potent ML1 inhibitor (13, 24), worsened the dystrophic 
phenotype in mdx mice (fig. S4, G to K). Furthermore, in ML1 KO 
mice that also exhibit a DMD-like phenotype such as necrosis and 
central nuclei (13), no obvious ML-SA5 rescue effects were seen 
(Fig. 4, F and G). Hence, the actions of ML-SA5 are likely to be 
mediated through ML1 (i.e., on target). Last, at the behavioral level, 
motor performance in a downhill treadmill test improved markedly 
following ML-SA injection in mdx mice (Fig. 4H). Therefore, similar 
to the genetic overexpression studies, pharmacological activation of 
ML1 in vivo using small molecules was also muscle protective.
ML1 facilitates sarcolemma repair, thereby reducing skeletal 
and cardiac muscle damage in mdx mice
One of the major causes of muscular dystrophy is defective sarco-
lemma repair, and lysosomal exocytosis is a primary route for reseal-
ing damaged membranes (25). Given the essential role of ML1 in 
lysosomal exocytosis and membrane resealing (13), it is likely that 
ML1’s muscle protective effects are mediated by sarcolemma repair. 
Skeletal muscle damage was experimentally induced in vivo with a 
short-term treadmill exercise protocol (26) and confirmed with the 
entry of the membrane-impermeable Evans blue (EB) dye (13). The 
percentage of EB-positive fibers, which never exceeded 2% in WT 
muscles, reached 9% at rest and 18% after treadmill exercise in mdx 
muscles (Fig. 5, A and B). Notably, mdx;ML1MCK mice had less than 
2% of EB-positive muscle fibers, even after treadmill exercise (Fig. 5, 
A and B, and fig. S5, A and B). EB uptake was also much reduced in 
ML-SA–treated mdx muscle (Fig. 5, C and D, and fig. S5, C and D) 
but increased in ML-SI–treated mdx mice (fig. S4, J and K). Like-
wise, when cardiomyocyte damage was induced in young (2-month-old) 
mdx mice with isoproterenol, EB uptake in the heart tissues was much 
reduced by ML-SA5 injection (Fig. 5, E and F). Collectively, these 
results suggest that compromised membrane integrity in both skeletal 
and cardiac muscles can be improved by ML1 up-regulation.
We also performed an ex vivo muscle damage test, in which in 
situ force in GAS muscles was measured before and after mechanical 
stretch by blind experimenters (27). The muscle force deficit seen in 
mdx mice was markedly reduced with ML1 overexpression (Fig. 5G), 
showing that ML1 expression has the potential to protect muscles 
from contraction-induced muscle damage in vivo. To study mem-
brane repair in vitro, we used FM 4-64 dye to detect membrane dis-
ruptions (8) in single myofibers isolated from the flexor digitorum 
brevis (FDB) muscle (8, 9). Upon laser irradiation, mdx fibers 
continued to take up FM dye at the injury sites for several minutes, 
whereas FM dye uptake was much reduced in ML1-overexpressed 
mdx muscle (Fig. 5, H and I). These results suggest that ML1 activation 
facilitates membrane repair to reduce muscle damage in mdx mice.
Up-regulation of ML1 in muscle activates transcriptional 
factor EB and corrects lysosomal insufficiency
Expression of lysosome-associated membrane protein 1 (Lamp1) 
is an indicator of lysosome function in vivo such that Lamp1 
up-regulation accompanies lysosomal dysfunction or insufficiency 
(28). Aberrant Lamp1 expression has been reported in several mdx 
studies (29, 30). We found that Lamp1 levels were increased in mdx 
compared with WT mice in both GAS and DIA isolated from 
1-month-old animals (Fig. 6, A to D). In our immunofluorescence 
analysis, Lamp1 up-regulation was apparent in both muscle fibers 
and surrounding cells (e.g., infiltrated macrophages; Fig. 6A and fig. 
S5E), suggesting that inflammation, which is known to be associated 
with necrosis (31), may also contribute to Lamp1 up-regulation. 
Collectively, these results suggest that there is lysosome insufficiency 
in the muscle tissues of mdx mice and that lysosome biogenesis might 
have been weakly activated to compensate for the deficiency.
ML1 activation has been reported to increase lysosome biogenesis 
and Lamp1 levels through nuclear translocation of transcriptional 
factor EB (TFEB), a master regulator of lysosomal genes (18, 32). 
Lamp1 expression was significantly lower in mdx;ML1MCK mice 
compared to mdx mice (Fig. 6, A to D). Likewise, the aberrant 
up-regulation of TFEB was also corrected by ML1 overexpression 
or activation (see fig. S5, F to H). These seemingly puzzling results 
may be explained by the fact that ML1 expression boosts lysosome 
function and decreases necrosis in muscle, obviating the need for 
compensatory changes via the expression of lysosomal genes. In 
mdx;ML1MCK mice or ML-SA5–injected mdx mice, TFEB nuclear 
translocation was increased (Fig. 6, E and F, and fig. S5F), but Lamp1 
and TFEB up-regulation and other compensatory lysosomal changes, 
e.g. increased LC3-II levels, were suppressed (Fig. 6, G and H, and 
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fig. S5, F to I). Hence, ML1 activation may further boost lysosome 
function to override lysosome insufficiency, yielding muscle protec-
tive effects. Similar scenarios have been reported in several lysosomal 
storage disorders (LSDs), in which TFEB activation has been found 
to increase lysosome biogenesis in WT cells while suppressing Lamp1 
up-regulation in LSD animal models (14, 28).
ML1 protects human DMD muscle cells from damage 
through TFEB and lysosomal exocytosis
To study the role of ML1 activation in lysosome biogenesis directly, 
we used DMD cells, an immortalized myoblast line developed from 
a DMD patient’s muscle cells (fig. S6, A and B) (33). Only mild 
Lamp1 up-regulation was observed in DMD myoblasts (fig. S6C), 
suggesting that the lysosome insufficiency occurring in mdx mice 
might be caused by extensive in vivo muscle damage. Consistent 
with our lysosomal patch-clamp studies (Fig. 4A), nanomolar con-
centrations of ML1 agonists were sufficient to induce notable nuclear 
translocation of TFEB (fig. S6, D and E) and the related protein 
TFE3 (fig. S6, F and G). Consistently, expression of TFEB/TFE3 target 
genes, including those required for lysosome biogenesis and func-
tion, were elevated by ML-SA5 treatment (fig. S6H). Notably, TFEB 
mRNA and protein expressions were significantly reduced in 
ML-SA5–treated WT and DMD cells (fig. S6, H to K), suggestive 
of the negative feedback regulation. Hence, ML1 activation may lead 
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to TFEB nuclear translocation, thereby increasing lysosome bio-
genesis, which, in turn, reduces lysosome stress and restores lyso-
some homeostasis.
Whereas increased TFEB activation and lysosome biogenesis may 
amplify lysosomal trafficking events including lysosomal exocytosis 
(34), ML1 activation alone can trigger lysosomal exocytosis directly 
(35). Membrane damage [i.e., chemical injury caused by streptolysin O 
(SLO) toxin] triggers lysosomal exocytosis and membrane repair (25). 
In myofibers, which contain a large cytoplasm, ML1-mediated lyso-
somal Ca2+ release, but not Ca2+ influx mediated by overexpressed 
ML1 channels (36) (see fig. S7, A to E), may preferentially activate 
lysosome-localized Ca2+ sensors to facilitate lysosomal exocytosis 
and biogenesis. Propidium iodide (PI) staining is a common read-
out for membrane damage and cell viability (37). In DMD myoblasts 
and differentiated myotubes, both membrane damage and ML-SA 
treatment induced lysosomal exocytosis (fig. S9, A and B), suggesting 
that ML-SAs may trigger membrane repair processes by mimicking 
a yet-to-be-identified damage signal. Consistent with this hypothesis, 
ML1 agonists and inhibitors decreased and increased, respectively, 
PI-positive cells following SLO treatment (fig. S8, A to D). The cyto-
protective effects of ML-SAs were abolished by knockdown of TFEB 
expression (fig. S8, E to H) or blockage of lysosomal exocytosis with 
dominant-negative synaptotagmin VII (Syt-VII) (fig. S9, C and D). 
Collectively, these results suggest that boosting ML1 activity may 
promote myocyte survival by reducing membrane damage via a 
direct and acute mechanism (i.e., lysosomal exocytosis), as well as 
through an indirect and more sustained mechanism (i.e., lysosome 
biogenesis; Fig. 6I).
DISCUSSION
ML1 deficiency causes a DMD-like muscle phenotype in both 
humans and rodents (13). In the current study, we found that both 
genetic and pharmacological activation of ML1 had muscle protec-
tive effects in mdx mice and human DMD muscle cells. ML1 activa-
tion led to TFEB nuclear translocation and increased lysosomal 
biogenesis while also increasing lysosomal trafficking (e.g., exocytosis), 
thereby facilitating sarcolemma repair to reduce muscle damage 
(Fig. 6I). Hence, our proof-of-concept study has provided strong 
evidence that small-molecule ML1 agonists can be developed to treat 
DMD. Upon withdrawal of ML-SA compounds, the muscle protec-
tive effects of the drugs disappeared (see fig. S10), suggesting that 
sustained or periodic activation of lysosome enhancement is required 
for DMD treatment. Although DMD is not an LSD per se (28), the 
observed compensatory changes are suggestive of lysosome insuffi-
ciency. In both cases, augmenting ML1/TFEB-dependent lysosome 
biogenesis can alleviate lysosome insufficiency. Since ML1 is a ubiq-
uitously expressed lysosomal channel, there could be “on-target” 
adverse effects of ML1 activation on nonmuscle issues in mdx mice. 
However, ML1/TFEB activation is most effective in cells/tissues with 
lysosome dysfunction/insufficiency, and ML1/TFEB-mediated lyso-
some biogenesis is suppressed by multiple mechanisms in healthy 
cells (28, 38). Hence, the on-target, “overstimulating” effects of ML1 
may be minimal on healthy cells/tissues/animals.
The simplest explanation for the presently observed muscle pro-
tective effect of ML1, in our view, would be facilitation of lysosomal 
exocytosis and membrane repair (Fig. 6I). However, although blockage 
of lysosomal exocytosis abolished ML1-dependent muscle protection, 
it should be noted that overexpression of Syt-VII dominant-negative 
constructs might indirectly affect lysosome biogenesis and TFEB- 
dependent functions. TFEB has been shown to be muscle protective 
in other studies as well (14). In LSDs, ML1 and TFEB form a positive 
feedback loop that promotes cellular clearance (28). It is possible that 
the same lysosome program may boost sarcolemma repair to reduce 
muscle damage in DMD and other muscle diseases. Hence, manip-
ulating lysosome function with small molecules may have broad 
therapeutic potential.
MATERIALS AND METHODS
Study design
The overall goal of this study was to determine the effect of ML1 
up-regulation on muscular dystrophy and membrane repair. All data 
presented here were replicated in at least four mice or three biolog-
ical replicates for in vitro experiments, with all histochemical stain-
ing data quantified by experimenters who were blind to genotypes/
treatments. On the basis of pilot studies of ML1 up-regulation on 
various pathologic hallmarks in mice, with a power of 0.8 and 
P < 0.05, we calculated a sample size of between 5 and 11 mice 
per group. Animals were randomly allocated into control and ex-
perimental groups.
Mouse lines
We generated muscle cell–specific ML1-overexpressing (ML1 
ROSA-lSl;MCK Cre or ML1MCK) mice by crossing ROSA-loxSTOPlox- 
GCaMP3-ML1 (abbreviated ML1 ROSA-lSl) mice with a muscle cell–
specific Cre line (MCK-Cre) (15). Mdx (001801) and utrophin+/−;mdx 
(014563) mice were purchased from The Jackson Laboratory. ML1−/− 
mice were provided by S. Slaugenhaupt (13). All mice used in the 
study were backcrossed to the C57BL/6 genetic background. Mice 
were used under the University of Michigan’s Institutional Animal 
Care and Use Committee’s approval. For cardiac function studies, 
only hemizygous male mice at the age of 13 to 15 months were used. 
For histological and physiological studies of skeletal muscles, 
both hemizygous male and homozygous female mdx mice were 
randomly assigned into different groups. The muscle type and age 
of the mice used for each experiment were indicated in the figures 
and legends.
Western blotting
After lysing muscle tissues in ice-cold radioimmunoprecipitation 
assay buffer with 1× protease inhibitor cocktail tablet (Roche), 20 to 
40 g of total protein aliquots were loaded into 4 to 12% bis-tris or 
3 to 8% tris-acetate SDS–polyacrylamide gradient gels (Invitrogen) 
and then transferred to polyvinylidene fluoride membranes via 
iBlot 2 Gel Transfer Device (Life Technologies). The membranes 
were blocked in 5% (w/v) skim milk in PBS with 0.05% Tween 20 
for 1 hour and then incubated overnight in the blocking buffer at 4°C. 
The primary antibodies used were as follows: anti-ML1 (ACC-081, 
Alomone Labs), anti–green fluorescent protein (GFP) (A6455, Invi-
trogen), anti-mouse Lamp1 [1D4B, Developmental Studies Hybridoma 
Bank (DSHB)], anti-human Lamp1 (H4A3, DSHB), anti-mouse TFEB 
(A303-673A, Bethyl), anti-human TFEB (4240, Cell Signaling Tech-
nology), anti-LC3 (L8918, Sigma), anti-dystrophin (ab15277, Abcam), 
anti-utrophin (8A4, DSHB), anti–-dystroglycan (sc-53987, Santa 
Cruz Biotechnology), and anti-GAPDH (glyceraldehyde 3-phosphate 
dehydrogenase) (MAB347, Millipore). Peroxidase-conjugated anti- 
rabbit, anti-mouse, or anti-rat secondary antibodies were applied at 
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room temperature for 1 hour, followed by SuperSignal West Pico 
Chemiluminescence Substrate (Thermo Fisher Scientific). Bands were 
quantitated in ImageJ software.
Immunofluorescence
Muscle tissues, harvested and frozen in 2-methylbutane, prechilled 
in liquid nitrogen, were cryosectioned at 12 m. After being washed 
with tris-buffered saline (TBS) + 0.025% Triton X-100, sections 
were blocked with 10% serum and 1% bovine serum albumin in 
TBS at room temperature for 2 hours. Cell lines and isolated primary 
cells cultured on coverslips were washed with PBS, fixed in 4% para-
formaldehyde, permeabilized in 0.3% Triton X-100 in PBS, and 
blocked in 1% bovine serum albumin in PBS. Fixed cells and cryo-
sections were then incubated at 4°C overnight with primary anti-
bodies targeting ML1, GFP, Lamp1, TFEB, dystrophin, or CD11b 
(M1/70.15.11.5.2, DSHB) at 1:50 or 1:200 solutions. Alexa Fluor 
secondary antibodies (Invitrogen) were then applied for 1 hour 
in the dark at room temperature, followed by 4′,6-diamidino- 
2-phenylindole counterstaining if necessary. Cells and tissue sec-
tions were imaged on a spinning disc confocal imaging system 
composed of an Olympus IX81 inverted microscope; 10×, 20×, 
and 60× Olympus objectives; a CSU-X1 scanner (Yokogawa); an 
iXon electron multiplying charge-coupled device camera (Andor); 
and MetaMorph Advanced Imaging acquisition software v.7.7.8.0 
(Molecular Devices). Image analysis results were quantified in 
MetaMorph software.
Primary muscle cell culture
Murine myoblasts were harvested and cultured as previously described 
(39). Briefly, skeletal muscles were isolated from P0 to P3 pups 
and dissociated with 0.25% trypsin supplemented with collagenase 
(2 mg/ml) (Sigma) at 37°C. To remove fibroblasts, cells were pre-
plated on a standard, non–tissue culture–coated petri dish for 60 to 
90 min. Muscle cells were then counted, seeded onto collagen-coated 
glass coverslips, and maintained at 37°C under 5% CO2 in F10 
medium supplemented with 20% fetal bovine serum (FBS) and 
penicillin/streptomycin. To induce differentiation, myoblasts were grown 
to confluence before switching to Dulbecco’s modified Eagle’s medium 
(DMEM) containing 5% horse serum and penicillin/streptomycin. 
Electrophysiology, Ca2+ imaging, and immunofluorescence labeling 
were performed after 3 days of differentiation induction to allow 
MCK-Cre expression.
Whole-endolysosome electrophysiology
Endolysosomal electrophysiology was performed on isolated endo-
lysosomes from muscle cells treated with 1 M vacuolin-1 to enlarge 
late endosomes and lysosomes (40, 41). The bath (internal/cytoplasmic) 
solution contained 140 mM K gluconate, 4 mM NaCl, 1 mM EGTA, 
2 mM Na2–adenosine 5′-triphosphate (ATP), 2 mM MgCl2, 0.39 mM 
CaCl2, 0.2 mM guanosine triphosphate (GTP), and 10 mM Hepes 
[pH adjusted with KOH to 7.2; the free [Ca2+]i was estimated to be 
~100 nM on Maxchelator software (https://bit.ly/2G7fIVH)]. The 
pipette (luminal) solution consisted of a low-pH Tyrode’s solution 
with 145 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM 
Hepes, 10 mM MES, and 10 mM glucose (pH 4.6). A perfusion system 
was used to ensure efficient solution exchange. Data were collected 
with an Axopatch 200A patch-clamp amplifier, Digidata 1440, and 
pClamp 10.0 software (Axon Instruments). Currents were digitized 
at 10 kHz and filtered at 2 kHz. All experiments were conducted at 
21° to 23°C, and all recordings were analyzed in pClamp 10.0 and 
Origin 8.0 (OriginLab, Northampton, MA).
GCaMP3 Ca2+ imaging
Ca2+ imaging was performed in ML1MCK and mdx;ML1MCK primary 
myotubes overexpressing GCaMP3-ML1 (15). The fluorescence in-
tensity at 488 nm (F488) was recorded with the spinning disc confocal 
imaging system.
Histochemical staining
Frozen sections were warmed to room temperature and hydrated in 
double-distilled (MilliQ) H2O. Tissues were stained with H&E dyes 
(Thermo Fisher Scientific) for the nucleus and cytoplasm, respectively, 
followed by gradient washing in ethanol (70, 90, and 100%) and 
xylene (100%). The stained sections were mounted in Permount 
medium (Thermo Fisher Scientific). Staining quantification was 
performed blindly following standardized operating procedures 
(SOP number: DMD_M.1.2.007). Necrotic myofibers, inflammatory 
cells, and fibroblasts were all counted as necrotic area. Collagen 
content was assessed with a Masson’s trichrome kit (Sigma). Area 
stained with blue color was quantified as fibrotic area.
Muscle force measurement
Mice were anesthetized by intraperitoneal injection of Avertin 
(tribromoethanol, 250 mg/kg) and placed on a warmed platform to 
maintain body temperature. GAS muscle contractile properties were 
measured in situ, as described previously (42). Briefly, after the GAS 
was isolated from surrounding tissues, the distal tendon was secured 
to the lever arm of a servomotor (model 6650LR, Cambridge Tech-
nology). The knee and foot were clamped to the platform. The muscle 
was activated by tibial nerve stimulation. With the muscle held at 
optimal length (L0), 300-ms trains of stimulus pulses were applied 
at increasing frequencies until the maximum isometric tetanic force 
(P0) was achieved. After the pre-stretch P0 (preP0) was recorded, we 
applied two stretches (12 s apart) of 30% of fiber length (Lf), which 
was estimated by multiplying L0 by previously determined Lf-to-L0 
ratios. After a 1-min rest, post-stretch P0 (postP0) was obtained to 
determine the force deficit. To maintain muscle temperature and 
moisture, a warm saline drip (37°C) was applied to the GAS contin-
uously throughout the procedure. After the experiment, mice 
were euthanized, and muscles were removed and trimmed of their 
tendons. Physiological cross-sectional areas were determined by 
dividing muscle mass by the product of Lf using a density of mam-
malian skeletal muscle of 1.06 g/cm3. Specific P0 (SP0) refers to 
P0 per cross-sectional area, and the force deficit was calculated as 
1 − postP0/preP0.
Echocardiography
Echocardiograms were performed by following the recommendations 
of the American Society of Echocardiography as described previously 
(43). All echocardiography experiments were performed by one reg-
istered echocardiographer who was blind to the mouse genotype. 
Before imaging, 13- to 15-month-old WT, mdx, and mdx;ML1MCK 
mice were weighed and anesthetized with inhaled isoflurane. Imaging 
was performed using a Vevo 770 Microimaging system (VisualSonics 
Inc.) equipped with an RMV707B (15 to 45 MHz) transducer. Left 
ventricular (LV) wall thickness was measured at end systole and end 
diastole. Mitral valve E and A wave inflow velocities were sampled 
at the tips of the mitral valve leaflets from the apical four-chamber 
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view. LV mass (LVM) was calculated using the formula LVM = 
1.053*[(LVID;d + LVPW;d + IVS;d)3 – LVID;d3], with the LV internal 
diameter (LVID), the LV posterior wall thickness (LVPW), and IVS 
being measured during diastole (d) from the parasternal short-axis 
view at the tip levels of the mitral valve leaflets.
Injection of small-molecule compounds
At P14, mdx mice were weighed and randomized into treatment 
groups. ML-SA compounds (dissolved in 10% DMSO, 40% PEG300, 
and 50% PBS) were administered to mice by intraperitoneal injec-
tion. After 14 days of daily injection, the mice were subjected to 
various behavioral tests or sacrificed for histological and biochemical 
analyses. For EB staining in the cardiac muscle and toxicity studies, 
drug injection was extended for one more month until the mice 
reached 2 months old. To induce cardiomyopathy in 2-month-old 
mdx mice, -isoproterenol (0.5 mg/kg) (Sigma) was injected subcu-
taneously 1 day before sacrificing (44). ML-SA and ML-SI compounds 
were identified initially by Ca2+ imaging–based high-throughput 
screening conducted at the National Institutes of Health (NIH)/
National Center for Advancing Translational Sciences (NCATS) 
Chemical Genomics Center (https://pubchem.ncbi.nlm.nih.gov/
bioassay/624414), and their potencies were improved by medicinal 
chemistry. All ML-SA and ML-SI compounds are available upon 
request under material transfer agreement with the University 
of Michigan.
Treadmill exercise
Mice were trained on an Exer-6M treadmill (Columbus Instruments). 
Before running, they were acclimated to the treadmill chamber for 
30 min. To induce damage, P28 mice ran on the treadmill with a 15° 
downgrade at 12 to 15 m/min for 30 min 1 day before being sacri-
ficed for analysis (26). To measure exhaustion time, the treadmill was 
set to a speed of 12 to 20 m/min.
Uptake of EB dye
Freshly prepared 1% (w/v) EB dye (Sigma) in PBS was injected 
intraperitoneally at 10 ml/kg 1 day before tissue collection.
Measurement of CK activity
Venous tail blood was collected before and after treadmill exercise, 
and serum was separated by centrifugation. Serum CK activity was 
measured with a Creatine Kinase Activity Assay kit (Abcam) follow-
ing the manufacturer’s instructions.
Complete blood count and liver biochemistry
Venous tail blood was collected in the EDTA tubes and sent to a 
laboratory test for complete blood count at room temperature im-
mediately after collection. For liver biochemistry, serum was sepa-
rated by centrifugation and stored at −80°C until sent for analysis.
Myofiber damage assay
After mice were sacrificed, FDB muscles were removed surgically 
and then digested in type I collagenase (2 mg/ml) (Sigma) at 37°C 
for 60 min. After trituration and resuspension in FluoroBrite 
DMEM solution (Thermo Fisher Scientific), single FDB fibers were 
mounted on a glass bottom dish precoated with Matrigel (Corning) 
and then stained with FM 4-64 dye (5 g/ml) (Thermo Fisher Scien-
tific) immediately before imaging. A Leica SP5 inverted confocal 
microscope system with a multiphoton laser (laser power of 2.3 W 
at wavelength 820 nm) was used to irradiate the fibers and take 
images. Fluorescence intensity at the injury site was measured by 
ImageJ software.
Muscle cell line culture
Immortalized human myoblast cell lines, including a WT line 
(ref. AB1079C38Q) and a DMD line (ref. AB1023DMD11Q: 
stop in exon 59), were provided by V. Mouly at the Institut de 
Myologie in France (45). Myoblasts were grown in KMEM (one 
volume of medium-199 + four volumes of DMEM, both from 
Thermo Fisher Scientific) supplemented with 20% FBS, fetuin 
(25 g/ml, Sigma), insulin (5 g/ml, Sigma), basic fibroblast growth 
factor (0.5 ng/ml, Thermo Fisher Scientific), human epidermal 
growth factor (5 ng/ml, Thermo Fisher Scientific), and dexa-
methasone (0.2 g/ml, Sigma) in a humidified CO2 incubator at 
37°C. Myoblasts were induced to differentiate into myotubes by 
switching to medium containing DMEM with gentamicin (50 g/ml) 
and insulin (10 g/ml).
RNA extraction and real-time quantitative  
polymerase chain reaction
Total RNA was extracted from cultured human myoblasts with 
TRIzol (Invitrogen) and then purified with a Turbo DNA-free kit 
(Invitrogen). Complementary DNA (cDNA) was then synthesized 
with a SuperScript III RT kit (Invitrogen). We conducted real-time 
quantitative polymerase chain reaction (PCR) with the PowerUp 
SYBR Green 2× Master Mix (Invitrogen) and the following PCR 
primers (32): HPRT [forward (fw), 5′-tggcgtcgtgattagtgatg-3′; reverse 
(rev), 5′-aacaccctttccaaatcctca-3′], PGC1 (fw, 5′-catgcaaatcacaat-
cacagg-3′; rev, 5′-ttgtggcttttgctgttgac-3′), MCOLN1 (fw, 5′-gagtgg-
gtgcgacaagtttc-3′; rev, 5′-tgttctcttcccggaatgtc-3′), ATP6V0E1 (fw, 
5′-cattgtgatgagcgtgttctgg-3′; rev, 5′ -aactccccggttaggaccctta-3′), 
ATP6V1H (fw, 5′-ggaagtgtcagatgatcccca-3′; rev, 5′-ccgtttg-
cctcgtggataat-3′), CTSF (fw, 5′-acagaggaggagttccgcacta-3′; rev, 
5′-gcttgcttcatcttgttgcca-3′), TFEB (fw, 5′-caaggccaatgacctggac-3′; 
rev, 5′-agctccctggacttttgcag-3′), CTSD (fw, 5′-cttcgacaacctgatg-
cagc-3′; rev, 5′-tacttggagtctgtgccacc-3′), PPP3CA (fw, 5′-gctgccct-
gatgaaccaac-3′; rev, 5′-gcaggtggttctttgaatcgg-3′), DPP7 (fw, 5′-gat-
tcggaggaacctgagtg-3′; rev, 5′-cggaagcaggatcttctgg-3′), CTSB (fw, 
5′-agtggagaatggcacacccta-3′; rev, 5′-aagagccattgtcacccca-3′), TPP1 
(fw, 5′-gatcccagctctcctcaatac-3′; rev, 5′-gccatttttgcaccgtgtg-3′), and 
NEU1 (fw, 5′-tgaagtgtttgcccctggac-3′; rev, 5′-aggcaccatgatcatcgctg-3′).
Silencing RNA knockdown
TFEB expression was transfected with small interfering RNA (siRNA) 
oligonucleotides (5′-gaaaggagacgaagguucaacauca-3′) and Lipofect-
amine 2000 (both from Invitrogen). Cells were subjected to bio-
chemical and cell biological analyses 72 hours after transfection.
Flow cytometry PI staining
Cells were pretreated with various compounds, digested in Ac-
cutase, and then washed with Tyrode’s solution supplemented 
with 20% FBS. After counting, cell membranes were damaged 
with SLO toxin (1 g/ml, 10 min) at 37°C. His-tagged SLO (carry-
ing a cysteine deletion that eliminates the need for thiol activation) 
(37) was provided by R. Tweeten (University of Oklahoma, Norman, 
OK) and purified as described previously (13). SLO-treated cells 
were stained with PI (2 g/ml) (Thermo Fisher Scientific) for 
5 min and analyzed by the Attune NxT Acoustic Focusing Cytometer 
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(Life Technologies). Total cell events were measured with Vybrant 
DyeCycle Violet stain (Invitrogen). At least 10,000 cells were used 
for each experimental group. Data were analyzed in Attune NxT 
software.
Lamp1 surface labeling
After 3 days of differentiation, immortalized human myotubes pre-
treated with ML-SAs were incubated with SLO (0.5 to 1 g/ml) at 
37°C for 30 min. Nonpermeabilized cells were labeled with anti-human 
Lamp1 (H4A3) antibody, which recognizes a luminal epitope, at 4°C 
for 1 hour. Cells were then fixed in 2% paraformaldehyde for 30 min 
and incubated with Alexa Flour 488–conjugated secondary antibody 
(Invitrogen) at room temperature for 1 hour.
Statistical analysis
Data are presented as the means ± SEM. Statistical comparisons were 
performed with analyses of variance (ANOVAs) and Turkey’s post 
hoc tests or with paired and unpaired Student’s t tests where appro-
priate. A value of <0.05 was considered statistically significant.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/6/eaaz2736/DC1
Fig. S1. Muscle-specific transgenic overexpression of ML1.
Fig. S2. Muscle-specific transgenic overexpression of ML1 reduces GAS, DIA, and cardiac 
pathologies in mdx mice.
Fig. S3. Pharmacokinetics and toxicity of ML-SA5.
Fig. S4. ML1 agonist injection (intraperitoneal) ameliorates GAS and DIA pathologies in mdx mice.
Fig. S5. Activation of ML1 corrects lysosomal insufficiency and improves sarcolemmal repair in 
mdx mice.
Fig. S6. ML1 agonist activates TFEB/TFE3 and lysosomal biogenesis in DMD myoblasts.
Fig. S7. Sarcolemmal Ca2+ entry is not required for ML-SA–induced TFEB nuclear translocation.
Fig. S8. ML1 agonist prevents cell death in DMD myoblasts via TFEB.
Fig. S9. Lysosomal exocytosis is required for ML-SA5–induced sarcolemma repair and cell survival.
Fig. S10. Requirement of continuous agonist administration in achieving muscle protective effects.
View/request a protocol for this paper from Bio-protocol.
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